Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals
COVID-19 vaccine clinical development was conducted with unprecedented speed. Immunity measurements were concentrated on the antibody response which left significant gaps in our understanding how robust and long-lasting immune protection develops. Better understanding the cellular immune response wi...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.880784/full |
| _version_ | 1811335689679142912 |
|---|---|
| author | Eustache Paramithiotis Scott Sugden Eszter Papp Marie Bonhomme Todd Chermak Stephanie Y. Crawford Stefanie Z. Demetriades Gerson Galdos Bruce L. Lambert John Mattison John Mattison Thomas McDade Stephane Pillet Robert Murphy |
| author_facet | Eustache Paramithiotis Scott Sugden Eszter Papp Marie Bonhomme Todd Chermak Stephanie Y. Crawford Stefanie Z. Demetriades Gerson Galdos Bruce L. Lambert John Mattison John Mattison Thomas McDade Stephane Pillet Robert Murphy |
| author_sort | Eustache Paramithiotis |
| collection | DOAJ |
| description | COVID-19 vaccine clinical development was conducted with unprecedented speed. Immunity measurements were concentrated on the antibody response which left significant gaps in our understanding how robust and long-lasting immune protection develops. Better understanding the cellular immune response will fill those gaps, especially in the elderly and immunocompromised populations which not only have the highest risk for severe infection, but also frequently have inadequate antibody responses. Although cellular immunity measurements are more logistically complex to conduct for clinical trials compared to antibody measurements, the feasibility and benefit of doing them in clinical trials has been demonstrated and so should be more widely adopted. Adding significant cellular response metrics will provide a deeper understanding of the overall immune response to COVID-19 vaccination, which will significantly inform vaccination strategies for the most vulnerable populations. Better monitoring of overall immunity will also substantially benefit other vaccine development efforts, and indeed any therapies that involve the immune system as part of the therapeutic strategy. |
| first_indexed | 2024-04-13T17:27:59Z |
| format | Article |
| id | doaj.art-8cb3ccf9b1a44d5c9c719d379ae3a20b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T17:27:59Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8cb3ccf9b1a44d5c9c719d379ae3a20b2022-12-22T02:37:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-05-011310.3389/fimmu.2022.880784880784Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised IndividualsEustache Paramithiotis0Scott Sugden1Eszter Papp2Marie Bonhomme3Todd Chermak4Stephanie Y. Crawford5Stefanie Z. Demetriades6Gerson Galdos7Bruce L. Lambert8John Mattison9John Mattison10Thomas McDade11Stephane Pillet12Robert Murphy13Research and Development, CellCarta, Montreal, QC, CanadaScientific Team, CellCarta, Montreal, QC, CanadaGlobal Research and Development, CellCarta, Montreal, QC, CanadaVaccine Sciences Division, Pharmaceutical Product Development (PPD) Inc., Wilmington, NC, United StatesRegulatory and Government Affairs, CellCarta, Montreal, QC, CanadaDepartment of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, IL, United StatesCenter for Communication and Health, Northwestern University, Evanston, IL, United StatesRobert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United StatesCenter for Communication and Health, Northwestern University, Evanston, IL, United StatesHealth Information, Kaiser Permanente, Pasadena, CA, United States0Health Technology Advisory Board, Arsenal Capital, New York, NY, United States1Department of Anthropology, Northwestern University, Evanston, IL, United States2McGill University Health Center, Montreal, QC, CanadaRobert J. Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United StatesCOVID-19 vaccine clinical development was conducted with unprecedented speed. Immunity measurements were concentrated on the antibody response which left significant gaps in our understanding how robust and long-lasting immune protection develops. Better understanding the cellular immune response will fill those gaps, especially in the elderly and immunocompromised populations which not only have the highest risk for severe infection, but also frequently have inadequate antibody responses. Although cellular immunity measurements are more logistically complex to conduct for clinical trials compared to antibody measurements, the feasibility and benefit of doing them in clinical trials has been demonstrated and so should be more widely adopted. Adding significant cellular response metrics will provide a deeper understanding of the overall immune response to COVID-19 vaccination, which will significantly inform vaccination strategies for the most vulnerable populations. Better monitoring of overall immunity will also substantially benefit other vaccine development efforts, and indeed any therapies that involve the immune system as part of the therapeutic strategy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.880784/fullcellular immunityimmunocompromisedvaccineCOVID-19efficacy |
| spellingShingle | Eustache Paramithiotis Scott Sugden Eszter Papp Marie Bonhomme Todd Chermak Stephanie Y. Crawford Stefanie Z. Demetriades Gerson Galdos Bruce L. Lambert John Mattison John Mattison Thomas McDade Stephane Pillet Robert Murphy Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals Frontiers in Immunology cellular immunity immunocompromised vaccine COVID-19 efficacy |
| title | Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals |
| title_full | Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals |
| title_fullStr | Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals |
| title_full_unstemmed | Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals |
| title_short | Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals |
| title_sort | cellular immunity is critical for assessing covid 19 vaccine effectiveness in immunocompromised individuals |
| topic | cellular immunity immunocompromised vaccine COVID-19 efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.880784/full |
| work_keys_str_mv | AT eustacheparamithiotis cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT scottsugden cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT eszterpapp cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT mariebonhomme cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT toddchermak cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT stephanieycrawford cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT stefaniezdemetriades cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT gersongaldos cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT brucellambert cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT johnmattison cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT johnmattison cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT thomasmcdade cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT stephanepillet cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals AT robertmurphy cellularimmunityiscriticalforassessingcovid19vaccineeffectivenessinimmunocompromisedindividuals |